Characterized by angiogenesis and inflammation, cancer is a major public health problem and a complex terminal disease worldwide, which is injurious to human health and lives[@b1][@b2]. With the aging population together with increasing formation of cancer-causing habits, it is estimated that there would be more than 22 million new cases suffering from cancer in the next decades. Therefore, the clinical and economic burden of cancer on healthcare will be heavier[@b2][@b3]. Although the mechanism of carcinogenesis has not been completely clarified, abundant evidences indicated that a combination of genetic predisposition and environmental exposures is believed to contribute to pathogenesis of cancer[@b4]. With numerous recent advances in genetic research, many genes that are related to malignancy susceptibility have been identified as candidates in multiple populations, especially nuclear factor-kappa B 1 (*NFKB1*)[@b5][@b6][@b7][@b8][@b9][@b10].

There is mounting evidence that inflammatory cytokines and carcinogens closely related to cancer development are involved in activating the common cell survival signaling pathways[@b11][@b12]. NF-κB serves as a major cell survival signal and is involved in multiple steps in carcinogenesis and in cancer cell's resistance to chemo- and radiotherapy[@b12][@b13]. It was identified as an inducible transcriptional factor binding to the intronic enhancer of the kappa light chain gene in every cell type[@b14][@b15]. Subsequently, NF-κB acts as an important regulator of more than 200 genes known to be involved in cell adhesion, cell survival, inflammation, apoptosis, and growth[@b16][@b17]. The NF-κB family is composed of five members in mammal: p50/p105, p65/RelA, c-Rel, RelB, and p52/p100 (NFKB2), which can form different dimeric combinations. *NFKB1* gene, mapped to chromosome 4q24, encodes p105/p50 isoforms of NF-κB, involved in cancer initiation and progression. The *-94 insertion/deletion* (ins/del) *ATTG* polymorphism within the promoter region of the *NFKB1* gene could potentially affect the transcription of the gene and the function of NF-κB protein, sequentially leading to loss of binding capacity to nuclear proteins and reduced promoter activity[@b18].

The *-94 ins/del ATTG* (rs28362491) polymorphism that involves deletion of four nucleotides in the promoter region of *NFKB1* gene consists of three genotypes: homozygote insertion or wild-type (WW), homozygote deletion or variant (DD), and heterozygous ins/del (DW)[@b7][@b18]. According to published data, several search groups have investigated the relationship between the polymorphism and cancers risk[@b7][@b10][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27]. However, these results obtained remains inconsistent. For instance, numerous studies reported that the del/del genotype of the polymorphism could contribute to an increased colorectal cancer (CRC)[@b28][@b29][@b30], papillary thyroid carcinoma (PTC)[@b24] and lung cancer (LC)[@b13] in Chinese or Caucasian populations, while some other studies showed that the ins/ins genotype of the polymorphism could increase the risk of CRC[@b20][@b31], LC[@b26] and bladder cancer (BC)[@b32] in different populations. In addition, several studies showed a lack of relationship between the polymorphism and CRC risk[@b7].

Up to now, some earlier meta-analyses based on different strategies have tried to investigate the link between the polymorphism and cancer risk. Yang *et al*.[@b33] and Nian *et al*.[@b34] reported that the *-94 ins/del ATTG* polymorphism was significantly associated with decreased cancer risk in Asian populations, but not in Caucasian populations. Unfortunately, the two previous meta-analyses included some studies, in which the genotype distributions of control groups were not consistent with Hardy--Weinberg equilibrium (HWE). In addition, obviously high heterogeneity was detected under all five genetic models in their studies, but they only conducted subgroup analysis based on ethnicity to investigate the origin of the high heterogeneity. Furthermore, the authors did not perform tests to access statistical significance of multiple null hypotheses[@b35]. Henceforth, some new studies further assessed the relationship between the polymorphism and cancer risk among multiple ethnic populations. However, the association remains inconclusive due to the inconsistent results from the published publications[@b23][@b24][@b25][@b26][@b27][@b30][@b36][@b37][@b38][@b39][@b40][@b41][@b42]. Therefore, the data need to be updated and more reliable evaluations of the polymorphism with cancer risk are warranted.

Due to the inconsistency of past studies and the critical role of the variant in the pathogenesis of cancer, we conducted an updated meta-analysis to investigate the association of *NFKB1 -94 ins/del ATTG* promoter polymorphism and cancer risk by precise results.

Materials and Methods
=====================

Study selection
---------------

A systematic search of PubMed, Embase, ISI Web of Science, and Chinese National Knowledge Infrastructure (CNKI) database was conducted by two independent reviewers to identify relevant articles, which had investigated the association between *NFKB1 -94 ins/del ATTG* polymorphism and susceptibility to cancer (latest electronic search was updated on March 10, 2016). The search terms were used as follows: 'cancer' or 'carcinoma' or 'tumor' or 'carcinogenesis' or 'neoplasm' And 'NF-κB' or 'Nuclear factor-κB 1' or 'NFKB1" And 'polymorphism' or 'variant' or 'mutation' or 'polymorphisms' or 'variants' or 'mutations'. No publication date or languages restrictions were imposed. Studies eligible for this meta-analysis must fulfill the following inclusion criteria: (a) studies using a case-control design; (b) studies evaluating the association between *NFKB1 -94 ins/del ATTG* polymorphism and cancer risk; (c) genotype distributions should be available for estimating the odds ratios (OR) with 95% confidence interval (CI); (d) the genotype distributions among control groups must be consistent with HWE. For multiple reports based on overlapping samples, only the most recent study or the study with the largest number of subjects were retained. Exclusion criteria were defined as follows: (a) abstracts, conferences, reviews, letters, case reports, and non-human studies; (b) repeated or overlapping publications; (c) studies reporting neither genotype distributions nor allele frequency; (d) the studies that do not follow HWE. We also inspected the references list of reviews or previous meta-analyses for potentially relevant publications. Two investigators independently screened all abstracts and citations to extract potentially eligible studies.

Data extraction
---------------

Two investigators independently collected the information of each eligible study based on the inclusion and exclusion criteria. First author, publication year, country, ethnicity, control source, genotyping technology, genotype and allele distributions, total number of cases and controls, and cancer type were extracted. In case of discrepancies, we checked the collected data and reached a consensus through discussion to ensure accuracy of the data. The information is shown in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

Quality score assessment
------------------------

The quality of included studies was estimated according to the Newcastle--Ottawa Scale (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). The scale use a '-' rating system to evaluate quality based on three points including the selection of the study groups, comparability of the groups, and the ascertainment of the exposure or outcome of interest in the case-control study. Total scores range from 0 to 9 points. A study with scores of more than 7 points was considered to be a high quality study ([Table 1](#t1){ref-type="table"}). Discrepancies would be resolved by discussion with a third author until a consensus was reached.

Statistical method
------------------

In this meta-analysis, all of the data in eligible studies were calculated as odds ratios (OR) with 95% confidence interval (CI) to assess the strength of association between *NFKB1 -94 ins/del ATTG* promoter polymorphism and the risk of cancer. The *-94 ins/del ATTG* polymorphism consists of three genotypes: homozygous insertion or wild-type (WW), homozygous deletion or variant (DD), and heterozygous ins/del (DW). The pooled OR was estimated in five genetic models: (1) dominant model: del/del + del/ins versus ins/ins (DD+DW vs. WW); (2) recessive model: del/del versus del/ins + ins/ins (DD vs. DW+WW); (3) homozygous model: del/del versus ins/ins (DD vs. WW); (4) heterozygous del/ins versus ins/ins (DW vs. WW); and (5) allelic model: deletion allele versus insertion allele (D vs. W), which was considered statistically significant when the P value of the Z test was less than 0.05.

Heterogeneity among studies was evaluated by Chi-squared-based Q-test and I^2^ statistics, which confirmed the heterogeneity at *P*-value \< 0.10. If no or low heterogeneity existed (*P* \< 0.10), the random-effects model (REM) was applied to estimate pooled OR. Otherwise, the fixed-effects model (FEM) was used. Moreover, HWE was recalculated in control groups by Pearson's *χ*^*2*^ test before this meta-analysis was conducted. To explore the potential heterogeneity among studies, we conducted subgroup analysis based on ethnicity (Asian and Caucasian), control source (hospital-based (HB) and population-based (PB) population), genotyping method (TaqMan and others), quality score of studies, and type of cancer. In addition, sensitivity analyses were also conducted through sequentially excluded individual studies to investigate the potential origin of heterogeneity and to assess the stability of the results.

Potential publication bias was tested by several methods. Visual inspection of asymmetry in funnel plots was carried out. Furthermore, Egger' regression and Begg's test were also utilized to detect publication bias, and *P* \< 0.05 was considered statistically significant. Benjamini--Hochberg false discovery rate (FDR) test was used to correct for multiple comparisons yielding P~corr~ value less than 0.05 was considered as significant. All statistical analyses were performed with STATA 12.0 software (Stata Corp LP, College Station, TX).

Results
=======

Study inclusion and characteristics
-----------------------------------

This meta-analysis design was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) prospectively. The process of study selection was showed in [Fig. 1](#f1){ref-type="fig"}. We totally identified 419 articles with our search strategy. After removing duplications, scanning titles and abstracts and reading the full-text, 36 articles were eligible based on our inclusion and exclusion criteria in this meta-analysis. Among these selected articles, Riemann *et al*.[@b43] and Li *et al*.[@b39] investigated the link between the *-94 ins/del ATTG* polymorphism and the risk of three different cancer types, respectively. Therefore, we treated them as six separate comparisons. In addition, Huang *et al*.[@b44] and Liu *et al*.[@b41] conducted their research in two different places (eastern and southern china), which were treated as four individual comparisons. Therefore, a total of 42 studies from 36 articles were identified, including 43,000 subjects (18,222 cases and 24,778 controls)[@b8][@b10][@b13][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b32][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55]. Of the 42 included studies, five studies involving 7,186 subjects reported on colorectal cancer (CRC). In the remaining studies, there were two studies on renal cell carcinoma (RCC), four studies on bladder cancer (BC), two studies on gastric cancer (GC), three studies on hepatocellular carcinoma (HCC), four studies on prostate cancer (PC), four studies on ovarian cancer (OC), five studies on lung cancer (LC), three studies on nasopharyngeal carcinoma (NPC), two studies on oral squamous cell carcinoma (OSCC). Other cancers, such as multiple myeloma, breast cancer, cervical squamous cell carcinoma, acute myeloid leukaemia, were relatively less investigated and thereby merged into "other cancer" category. In addition, there were 30 studies for the Asian population and 12 studies for the Caucasian population. As for control source, 10 studies employed PB control, while 29 studies conducted their studies applying HB control. Moreover, the estimated quality of each study was in the range of 6--9 points. The genotype distributions for control populations in all studies were conformed to HWE. Characteristics of included studies are shown in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}.

Quantitative data synthesis
---------------------------

The meta-analysis results have been summarized in [Table 3](#t3){ref-type="table"}. For the presence of moderate heterogeneity across all levels of analysis, random-effects model (REM) was applied to calculate the summary odds ratios (OR) in all five genetic models ([Table 4](#t4){ref-type="table"}). Overall, a significantly decreased risk of cancer was associated with *NFKB1 -94 ins/del ATTG* polymorphism in all five genetic models (DD+DW vs. WW: OR = 0.86, 95% CI = 0.79--0.95, *P* = 0.002; DD vs. DW+WW: OR = 0.84, 95% CI = 0.74--0.94, *P* = 0.003; DD vs. WW: OR = 0.77, 95% CI = 0.66--0.90, *P* = 0.001; DW vs. WW: OR = 0.90, 95% CI = 0.83--0.98, *P* = 0.011; D vs. W: OR = 0.89, 95% CI = 0.83--0.96, *P* = 0.002) ([Fig. 2](#f2){ref-type="fig"}). In addition, corrected *P* values for multiple testing remained significant ([Table 4](#t4){ref-type="table"}).

Subgroup analysis
-----------------

To investigate the moderate heterogeneity in the outcomes and the inference of the studies, we pooled the odds ratios (OR) and 95% confidence interval (CI) from further subgroup analyses of ethnicity, control source, genotyping method, cancer type, and quality score. When stratified by control source, REM was utilized due to the presence of heterogeneity in all above genetic models ([Table 4](#t4){ref-type="table"}). Consistently, *NFKB1 -94 ins/del ATTG* polymorphism was significantly associated with decreased cancer susceptibility among HB population in all genetic models, among which the most obvious is for dominant model (DD+DW vs. WW: OR = 0.85, 95% CI = 0.77--0.95, *P* = 0.003), and weakest for recessive model (DD vs. DW+WW: OR = 0.86, 95% CI = 0.74--0.99, *P* = 0.04). Corrected *P* values for multiple testing remained significant. However, no such significant relationship was detected for PB population in any genetic model ([Table 3](#t3){ref-type="table"}).

Subgroup analysis based on ethnicity was also conducted in this analysis. Since moderate heterogeneity was observed in all genetic models, we used the REM of analysis. The overall results showed that a significantly strong association between *NFKB1 -94 ins/del ATTG* polymorphism and decreased cancer risk was seen for Asian population in all genetic models (DD+DW vs. WW: OR = 0.77, 95% CI = 0.70--0.86, *P* \< 0.0001; DD vs. DW+WW: OR = 0.77, 95% CI = 0.67--0.90, *P* = 0.001; DD vs. WW: OR = 0.66, 95% CI = 0.55--0.80, *P* \< 0.0001; DW vs. WW: OR = 0.85, 95% CI = 0.81--0.90, *P* \< 0.0001; D vs. W: OR = 0.82, 95% CI = 0.76--0.90, *P* \< 0.0001) ([Fig. 3](#f3){ref-type="fig"}). In contrast, the Caucasian population exhibit *NFKB1 -94 ins/del ATTG* promoter variant associated increased susceptibility to cancer in dominant (DD+DW vs. WW: OR = 1.20, 95% CI = 1.10--1.31, *P* \< 0.0001), homozygous (DD vs. WW: OR = 1.15, 95% CI = 1.01--1.31, *P* = 0.03), heterozygous (DW vs. WW: OR = 1.22, 95% CI = 1.11--1.34, *P* \< 0.0001), and allelic (D vs. W: OR = 1.11, 95% CI = 1.04--1.17, *P* = 0.001) models ([Table 3](#t3){ref-type="table"}), with low heterogeneity found in Caucasians ([Table 4](#t4){ref-type="table"}). Moreover, no significant variables were identified after corrections for multiple comparisons.

Subgroup analysis was conducted among 6 methods for genotyping. REM was used since moderate heterogeneity was identified in this subgroup analysis. In the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) group and polymerase chain reaction-polyacrylamide gel electrophoresis (PCR-PAGE) group, significantly decreased association between *NFKB1 -94 ins/del ATTG* promoter variant and cancer risk were identified, among which the most obvious is for recessive model in the two groups (PCR-RFLP group: DD vs. DW+WW: OR = 0.72, 95% CI = 0.60--0.87, *P* = 0.001; PCR-PAGE group: DD vs. DW+WW: OR = 0.65, 95% CI = 0.50--0.85, *P* = 0.002), respectively. In contrast, no relationship was detected in TaqMan, MassARRAY, PCR-CGE, and Pyrosequencing group ([Table 3](#t3){ref-type="table"}). When stratified by quality score, significant decreased association was only identified in the group whose quality score ≤ 7 points in dominant (DD+DW vs. WW: OR = 0.86, 95% CI = 0.76--0.97, *P* = 0.013), recessive (DD vs. DW+WW: OR = 0.81, 95% CI = 0.71--0.91, *P* = 0.001), homozygous (DD vs. WW: OR = 0.75, 95% CI = 0.63--0.89, *P* = 0.001), and allelic (D vs. W: OR = 0.87, 95% CI = 0.80--0.95, P = 0.002) model ([Table 3](#t3){ref-type="table"}).

In addition, stratification analysis by cancer type was also performed. Further analysis showed that the substitution was significantly related to decreased risk of OSCC (DD+DW vs. WW: OR = 0.60, *P* \< 0.0001; DD vs. DW+WW: OR = 0.63, *P* \< 0.0001; DD vs. WW: OR = 0.49, *P* \< 0.0001; DW vs. WW: OR = 0.67, *P* = 0.004; D vs. W: OR = 0.70, *P* \< 0.0001), OC (DD+DW vs. WW: OR = 0.67, *P* \< 0.0001; DD vs. DW+WW: OR = 0.68, *P* = 0.005; DD vs. WW: OR = 0.54, *P* \< 0.0001; DW vs. WW: OR = 0.73, *P* = 0.001; D vs. W: OR = 0.75, *P* \< 0.0001), and NPC (DD+DW vs. WW: OR = 0.82, *P* = 0.003; DD vs. DW+WW: OR = 0.74, *P* \< 0.0001; DD vs. WW: OR = 0.63, *P* \< 0.0001; D vs. W: OR = 0.83, *P* \< 0.0001) in genetic models. Moreover, significantly decreased relationship between the polymorphism and LC risk was only found in heterozygous model (DW vs. WW: OR = 0.84, 95% CI = 0.74--0.96, *P* = 0.008). In addition, corrected p values for multiple testing remained significant ([Table 4](#t4){ref-type="table"}). Nevertheless, there was no significant relationship between the polymorphism and the remaining cancer types in any genetic model, including CRC, RCC, BC, GC, HCC, PC and other cancer ([Table 3](#t3){ref-type="table"}).

Publication bias
----------------

Publication bias was assessed through the Begg's funnel plot and Egger's regression intercept tests. The shape of the Begg's funnel plot did not reveal basically asymmetric distribution in all comparisons of the overall population. Moreover, the result of Egger's test (dominant model: *P* = 0.269; recessive model: *P* = 0.202; homozygous model: *P* = 0.133; heterozygous model: *P* = 0.471; allelic model: *P* = 0.245) further provided no evidence of significant publication bias. Our observation of symmetric funnel plots and non-significant statistical tests confirmed no publication bias ([Fig. 4](#f4){ref-type="fig"}).

Sensitivity analyses
--------------------

To validate our results, we further conducted sensitivity analyses to evaluate the stability of these results in this meta-analysis. Firstly, the random-effects model was compared with the fixed-effects model, and the statistically similar results were obtained in all genetic models. Secondly, we applied leave-one-out method by sequentially excluding each study to assess the influence of individual study on the obtained conclusions. The conclusions remained unchanged in all comparisons, suggesting the stability of our meta-analysis. Furthermore, due to the higher number of studies of Asian population, we conducted the analysis with randomly selecting 50% of the case-control studies for many times to determine the sensitivity. However, the corresponding pooled ORs were generally similar in each comparison (data not shown). Therefore, our conclusion in this meta-analysis was stable and credible.

Discussion
==========

The NF-κB family constitutes a class of pleiotropic transcription factors, which seems to contribute to tumor angiogenesis and progression by regulating the transcription of genes involved in immune response, cell proliferation, apoptosis, and angiogenesis[@b17][@b56]. The NF-κB family members can form homo-dimmers and hetero-dimmers to produce more than 15 distinct active complexes, among which p50/p65 heterodimer is one of the most sufficient forms and is present in almost all cell types[@b57]. NF-κB complexes are constitutively active in various cancer cell lines and tissues, indicating the involvement of NF-κB in tumorigenesis[@b58][@b59]. In addition, various inflammatory cytokines, such as TNF-a, IL-6, and IL-8, regulated their biological effects by activating NF-κB. In consequence, the abnormality and disturbance of NF-κB function can reduce diverse biological processes, including uncontrolled cell proliferation and suppression of apoptosis, thereby rendering a cell more prone to malignant transformation[@b31].

A functional *-94 ins/del ATTG* (*rs28362491*) polymorphism in the promoter region of the p50/p105-encoding *NFKB1* gene located between two received key promoter regulatory elements modulates its transcription and then affects the production of protein subunits[@b18][@b31]. Previous studies have shown that the -94del allele may result in significantly decreased *NFKB1* transcript level and hence, reduce p50/p105 protein production[@b18][@b20]. Therefore, the different level of the protein subunits between the carriers of -94del allele and -94ins allele may be expected to contribute to inter-individual variations in cancer risk.

In this meta-analysis, we investigated the *-94 ins/del ATTG* on *NFKB1* gene locus with 42 separate case-control studies (18,222 cases and 24,778 controls) focusing on the relationship of this variant to cancer risk. The overall results revealed a significant association between -94 del/del variant genotype carriers and decreased cancer risk. Despite the mechanism remains unclear, considering the critical role of NF-κB in various biological pathways, we could hypothesize that ATTG deletion causes the loss of binding to nuclear proteins, which leads to reduced promoter activity[@b13]. The promoter sequence with -94 del allele results in lower transcriptional activity and thereby causes decreased levels of p50/p105 in the cytoplasm, which serves a critical function in trans-activating anti-apoptosis genes and inhibiting cell apoptosis, thereby promoting cellular proliferation. In addition, the p50 in -94 del carriers can form lesser heterodimers with p65 to mediate the inflammatory pathway compared to the -94 ins allele carriers. Therefore, the -94 del allele may play a protective role in cancer risk.

However, we must treat these results cautiously when referring to the findings, because moderate heterogeneity was detected in this meta-analysis, which may be attributed to different characteristics of the cohort, environmental exposure, clinical information and intrinsic complexity of cancer architecture. In addition, there are 30 studies for the Asian population and 12 studies for the Caucasian population. The high proportion of over-represented studies of the Asian population in the combined analysis clearly resulted in a bias, which affected the overall results. Therefore, we conducted a subgroup analysis to identify the origin of heterogeneity by ethnicity, control source, genotyping method, cancer type, and quality score.

When analysis was restricted to ethnicity, the variant del allele could confer a decreased or increased risk of developing cancer to its carriers among Asians and Caucasians, respectively. Natural selection and balance to other genetic variants may result in different genotype frequencies in different ethnicities. In addition, accumulated evidence demonstrated that individuals with the same genotype living in the different areas with different environments and life style might have a different cancer risk[@b7][@b20][@b31]. Therefore, this discrepancy between Caucasians and Asians could be attributed to the possible differences in genetic background, gene-environment, and non-genetic risk factors, such as smoking and high intake of salted foods. In populations where the -94del allele was identified to increase cancer risk, a plausible interpretation for such observation could be that the p50 protein lacks the C-terminal transactivation domain and may form inhibitory homo-dimers, which can serve as a role in repressing pro-inflammatory genes and then resulting in decreased levels of p50/p50 repressive homo-dimers in -94 del allele carriers[@b60][@b61]. Consequently, -94 del allele carriers may be genetically with a higher inflammatory response. Interestingly, the results were contrary to the results of two previous meta-analyses[@b33][@b34] that no significant association was seen between *NFKB1 -94 ins/del ATTG* polymorphism and the risk of cancer in Caucasians. The contradictory results are interpreted by the following reasons: (1) the small sample was included in the previous two meta-analyses. Therefore, the results may reduce the power to reveal a reliable relationship. There were twelve case-control studies eligible for this meta-analysis among Caucasians, so the result may be closer to the real value; (2) the previous studies included many studies, which do not follow HWE. These studies may make the result incredible; (3) the sensitivity analysis was conducted through three different methods in this meta-analysis, and the results were consistent with the previous results, suggesting the results of this study were stable; (4) different clinicopathological features of cases included, different experimental designs and genotyping methods utilized in these studies; (5) we used Benjamini--Hochberg procedures to adjust for multiple comparisons in setting the level of significance. There were no significant variables after corrections for multiple comparisons.

The stronger and significantly decreased risk of cancer when analysis was restricted to hospital-based (HB) group was observed in all genetic model, but such association was not seen in population-based (PB) group. Interestingly, it was noted that moderate heterogeneity appeared in the HB group, which may result from selection bias. Additionally, HB controls were selected from hospital, which may not validly represent the exposure situation of the overall population. Therefore, results from the PB controls were thought to be more reliable.

Cancer was an overly broad collection of different types, which may have confounding factors to not reveal a reliable association. Therefore, further stratification analysis by cancer type was also conducted. The decreased risk of cancer also remained in the subgroups of oral, ovarian, and nasopharyngeal carcinoma in Asian populations. Moreover, the clinical and demographic information are essential factors affecting the overall results. Zhang *et al*.[@b26] and Wang *et al*.[@b25] reported that the increased risk of *-94 ins/del ATTG* polymorphism remained when analyses were done according to gender and smoking status in lung cancer among Asian population. The study by Oltulu *et al*.[@b13] demonstrated that gender and age associated with lung cancer among Caucasian population. Additionally, Han *et al*.[@b38] demonstrated that the impact of the -*94 ins/del ATTG* polymorphism was not present in nonsmokers and younger subjects in prostate cancer. Consequently, only increasing the number of populations, without taking into clinical and demographic information into account, will not guarantee the validity of the results. We tried to collect some subsets of clinical information and demographic data from the eligible publications to conduct further analysis. However, on one side, the relatively small sample size could reduce the statistical power of this study and result in unreliable association. On the other side, these data were collected from various cancers and ethnicities, which may give rise to confounding variables to reveal an unreliable association. Therefore, in my opinion, a better result can be given exclusively from a case-control study of large sample size, the same cancer type, and the same ethnicity.

We note several potential limitations of this meta-analysis when interpreting these results. First, we were unable to perform further analysis to investigate other risk factors of cancer risk for insufficient original data, such as age, tumor location, and gene-environment/gene-gene interaction. Second, moderate between-study heterogeneity was checked in some genetic comparisons. Further subgroup analysis showed that cancer type and control source might be the source of heterogeneity. Nevertheless, there is other inexplicable heterogeneity affecting the results. Third, publication bias might have occurred for only including published articles. Some relevant published studies or unpublished studies with null results were missed, which may affect our results. Fourth, many studies included in this meta-analysis were performed in Asian and Caucasian populations, so the association needs to be verified in other ethnicities. Despite these limitations, we created a strict protocol, and performed study selection, data identification and statistical analysis to reduce potential bias through the whole process. Thus, the objectivity and reliability of the results are guaranteed.

In conclusion, to the best of our knowledge, this is a comprehensive study to assess the relationship between *NFKB1 -94 ins/del ATTG* polymorphism and cancer risk. Our results indicated that the *-94 ins/del ATTG* polymorphism was significantly associated with decreased cancer risk in Asian populations, but increased cancer risk in Caucasian populations. However, due to the limitations of this current meta-analysis, the conclusion might be not conclusive. Therefore, in the future, there will be a need for larger sample size and more ethnic groups to further confirm the results of this meta-analysis.
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###### Characteristics of 42 included studies in this meta-analysis.

  Author       Year   Country   Ethnicity   Cases/Control   Sample size   Control source   Cancer type    Genotyping method   Quality score
  ----------- ------ --------- ----------- --------------- ------------- ---------------- -------------- ------------------- ---------------
  Lin          2006    China      Asian        212/201          413             HB             OSCC           PCR-PAGE              6
  Riemann      2006   Germany   Caucasian      139/307          446             HB             CRC         pyrosequencing           7
  Riemann      2006   Germany   Caucasian      72/307           379             HB            BCCLL        pyrosequencing           7
  Riemann      2006   Germany   Caucasian      140/307          447             HB             RCC         pyrosequencing           7
  Riemann      2007   Germany   Caucasian      242/307          549             HB              BC         pyrosequencing           7
  Lehnerdt     2008   Germany   Caucasian      364/307          671             HB            HNSCC           PCR-RFLP              7
  Lo           2009    China      Asian        182/116          298             HB              GC            PCR-RFLP              6
  He           2009    China      Asian        202/404          606             HB             HCC            PCR-RFLP              7
  Zhang        2009    China      Asian        117/143          260             HB              PC            PCR-PAGE              8
  Zhou         2010    China      Asian        233/365          598           Mixed            CSCC           PCR-PAGE              7
  Andersen     2010   Denmark   Caucasian      378/756         1134             PB             CRC             TaqMan               8
  Tang         2010    China      Asian        207/228          435             HB              BC            PCR-PAGE              7
  Song         2011    China      Asian      1,001/1,005       2006             PB             CRC            PCR-RFLP              8
  Fan          2011    China      Asian        179/223          402             PB              OC             PCR-CGE              7
  Lin          2012    China      Asian        462/520          982             HB             OSCC            TaqMan               8
  Ungerback    2012   Sweden    Caucasian      348/622          966             PB             CRC             TaqMan               8
  Huang        2013    China      Asian       1056/1056        2112             HB              LC             TaqMan               7
  Huang        2013    China      Asian        503/623         1126             HB              LC             TaqMan               7
  Cheng        2013    China      Asian        135/520          655             HB             HCC             TaqMan               8
  Li           2013    China      Asian        609/640         1249             HB              BC             TaqMan               8
  Oltulu       2014   Turkey    Caucasian       95/99           194             NA              LC            PCR-RFLP              7
  Kopp         2013   Denmark   Caucasian      334/334          668             PB              PC             TaqMan               8
  Huo          2013    China      Asian        187/221          408             HB              OC            MassARRAY             7
  Vangsted     2012   Denmark   Caucasian     328/1696         2024             PB              MM             Taqman               6
  Zhou         2009    China      Asian        163/203          366             HB             NPC            PCR-PAGE              8
  Han          2015    China      Asian        936/936         1872             PB              PC            PCR-RFLP              8
  Li           2015    China      Asian        220/222          442             HB         Osteosarcoma       PCR-RFLP              7
  Liu          2015    China      Asian       906/1072         1978             HB             NPC             TaqMan               7
  Liu          2015    China      Asian        684/907         1591             HB             NPC             TaqMan               7
  Wang         2015    China      Asian        421/425          846             HB              LC            PCR-RFLP              8
  Lu           2015    China      Asian        687/687         1374             HB              OC            PCR-RFLP              7
  Kopp         2015   Denmark   Caucasian    1,010/1,829       2634             PB             CRC            PCR-KASP              6
  Chen         2015    China      Asian        411/438          852             HB              OC            MassARRAY             7
  Zhang        2014    China      Asian       208/1606         2230             HB             HCC            PCR-RFLP              6
  Hua          2014    China      Asian        401/433          834             HB              GC            MassARRAY             8
  Wang         2015    China      Asian        352/459          811             HB             PTC            PCR-PAGE              8
  Li           2015    China      Asian        730/780         1510             HB              BC             TaqMan               8
  Li           2015    China      Asian       1216/1588        2804             HB             RCC             TaqMan               8
  Li           2015    China      Asian        820/945         1765             HB              PC             TaqMan               8
  Rybka        2016   Poland    Caucasian      62/126           188             NA             AML             PCR-CGE              6
  Eskandari    2016    Iran       Asian        236/203          439             PB              BC             AS-PCR               9
  Zhang        2015    China      Asian        718/718         1436             PB              LC            PCR-RFLP              8

*AS-PCR,* Allele-Specific polymerase chain reaction*; PCR-CGE,* polymerase chain reaction with capillary gel electrophoresis; *PCR-RFLP*, polymerase chain reaction-restriction fragment length polymorphism; *PCR-PAGE*, polymerase chain reaction-polyacrylamide gel electrophoresis; *HB*, hospital-based study; *PB*, population-based study; *NA*, not available; *BC*, bladder cancer; *PC*, prostate cancer; *OC*, ovarian cancer; *LC*, lung cancer; *HCC*, hepatocellular carcinoma; *MM*, multiple myeloma; *OSCC*, oral squamous cell carcinoma; *CSCC*, cervical squamous cell carcinoma; *CRC*, colorectal cancer; *NPC*, nasopharyngeal carcinoma; *GC*, gastric cancer; *GNT*, gastroenteropancreatic neuroendocrine tumor; *HNSCC*, squamous cell carcinomas of the head and neck region; *BCLL*, B cell chronic lymphocytic leukemia; *RCC*, renal cell carcinoma; *ESCC*, esophageal squamous cell carcinoma; *BRC*, breast cancer; *PTC*, papillary thyroid carcinoma; *AML*, acute myeloid leukaemia.

###### Distributions of NF-κB1-94 ins/del ATTG promoter polymorphism allele and genotypes in different groups.

  Author       Case   Control                                                                                 
  ----------- ------ --------- ----- ------------ ------------- ----- ----- ----- ------------- ------------- -------
  Lin           50      103     59    203 (47.9)   221 (52.1)    58    100   43    216 (53.7)    186 (46.3)    0.993
  Riemann       27      58      54    112 (40.3)   166 (59.7)    48    141   118   237 (38.6)    377 (61.4)    0.586
  Riemann       13      41      18    67 (46.5)     77 (53.5)    48    141   118   237 (38.6)    377 (61.4)    0.586
  Riemann       17      76      47    110 (39.3)   170 (60.7)    48    141   118   237 (38.6)    377 (61.4)    0.586
  Riemann       30      124     88     184 (38)     300 (62)     48    141   118   237 (38.6)    377 (61.4)    0.586
  Lehnerdt      53      179     132   285 (39.2)   443 (60.8)    48    141   118   237 (38.6)    377 (61.4)    0.58
  Lo            31      89      62    151 (41.5)   213 (58.5)    34    62    20     130 (56)      102 (44)     0.361
  He            35      84      83    154 (38.1)   250 (61.9)    124   183   97    431 (53.3)    377 (46.7)    0.07
  Zhang         14      57      46    85 (36.3)    149 (63.7)    31    68    44    130 (45.5)    156 (54.5)    0.624
  Zhou          20      105     108   145 (31.1)   321 (68.9)    64    166   135   294 (40.3)    436 (59.7)    0.297
  Andersen      62      195     121   319 (42.2)   437 (57.8)    102   347   307   551 (36.4)    961 (63.6)    0.801
  Tang          26      92      89    144 (34.8)   270 (65.2)    46    108   74    200 (43.9)    256 (56.1)    0.565
  Song         138      500     363   776 (38.8)   1226 (61.2)   186   522   297   894 (44.5)    1116 (55.5)   0.102
  Fan           17      84      78     118 (33)     240 (67)     44    103   76    191 (42.8)    255 (57.2)    0.396
  Lin          100      246     116   446 (48.3)   478 (51.7)    168   271   81    607 (58.4)    433 (41.6)    0.099
  Ungerback     43      187     114   273 (39.7)   415 (60.3)    96    270   256   462 (37.1)    782 (62.9)    0.079
  Huang        225      459     372    909 (43)     1203 (57)    210   491   355   911 (43.1)    1201 (56.9)   0.089
  Huang        104      230     169   438 (43.5)   568 (56.5)    145   289   189   579 (46.5)    667 (53.5)    0.092
  Cheng         29      64      42    122 (45.2)   148 (54.8)    168   271   81    607 (58.4)    433 (41.6)    0.099
  Li           151      269     189   571 (46.9)   647 (53.1)    93    324   223   510 (39.8)    770 (60.2)    0.156
  Oltulu        16      44      35     76 (40)      114 (60)      6    47    46     59 (29.8)    139 (70.2)    0.18
  Kopp          54      152     128   260 (38.9)   408 (61.1)    64    161   109   289 (43.3)    379 (56.7)    0.741
  Huo           22      82      83    126 (33.7)   248 (66.3)    47    103   71    197 (44.6)    245 (55.4)    0.399
  Vangsted      55      163     110   273 (41.6)   383 (58.4)    253   778   665   1284 (37.9)   2108 (62.1)   0.303
  Zhou          22      67      74    111 (34.1)   215 (62.9)    42    90    71    174 (42.9)    232 (57.1)    0.177
  Han          534      339     63    1407 (75)     465 (25)     567   331   38    1465 (78.3)   407 (21.7)    0.23
  Li            46      114     60    206 (46.8)   234 (53.2)    66    106   50    238 (53.6)    206 (46.4)    0.55
  Liu          152      438     316    742 (41)     1070 (59)    224   512   336   960 (44.8)    1184 (55.2)   0.262
  Liu          117      331     236    565 (41)     803 (59)     195   438   274   828 (45.6)    986 (54.4)    0.169
  Wang          89      219     113   397 (47.2)   445 (52.8)    131   205   89    467 (54.9)    383 (45.1)    0.595
  Lu           221      351     115   793 (57.7)   581 (42.3)    253   339   95    845 (61.5)    529 (38.5)    0.271
  Kopp         146      449     320   741 (40.5)   1089 (59.5)   253   787   679   1293 (37.6)   2145 (62.4)   0.311
  Chen          95      195     120    385 (47)     435 (53)     122   235   85    479 (54.2)    405 (45.8)    0.136
  Zhang        107      312     205   526 (42.2)   722 (57.8)    274   790   542   1338 (41.7)   1874 (58.3)   0.631
  Hua          127      182     92    436 (54.4)   366 (45.6)    83    230   120   396 (45.7)    470 (54.3)    0.144
  Wang          60      186     106   306 (43.5)   398 (56.5)    79    209   171    367 (40)      551 (60)     0.273
  Li           187      316     227   690 (47.3)   770 (52.7)    124   395   261   643 (41.2)    917 (58.8)    0.208
  Li           188      577     451   953 (39.2)   1479 (60.8)   225   781   582   1231 (38.8)   1945 (61.2)   0.152
  Li           144      377     299   665 (40.6)   975 (59.4)    136   462   347   734 (38.8)    1156 (61.2)   0.371
  Rybka         7       30      25    44 (35.5)     80 (64.5)    14    69    43     97 (38.5)    155 (61.5)    0.08
  Eskandari     18      122     96    158 (33.5)   314 (66.5)    35    106   62    176 (43.3)    230 (56.7)    0.37
  Zhang         32      252     434    316 (22)     1120 (78)    76    290   352   442 (30.8)    994 (69.2)    0.16

*HWE*, Hardy-Weinberg equilibrium.

*WW*, homozygous insertion or wild-type; *DD*, homozygous deletion or variant; *DW*, heterozygous ins/del.

###### Summary of overall results and subgroup for the association between the NF-κB1-94 ins/del ATTG promoter polymorphism and cancer risk.

                        No.   Sample size (N)   DD+DI vs. II       DD vs. DI+II         DD vs. II           DI vs. II           D vs. I                                                                                                           
  -------------------- ----- ----------------- -------------- ----------------------- -------------- ----------------------- -------------- ----------------------- -------------- ----------------------- -------------- ----------------------- ---------------
  Overall               42        18,222           24,778      **0.86 (0.79--0.95)**    **0.002**     **0.84 (0.74--0.94)**    **0.003**     **0.77 (0.66--0.90)**    **0.001**     **0.90 (0.83--0.98)**    **0.011**     **0.89 (0.83--0.96)**     **0.002**
  Control source                                                                                                                                                                                                                                  
   PB                   10         5,369           8,212         0.90 (0.72--1.13)        0.354         0.77 (0.62--0.96)         0.02         0.72 (0.52--1.01)        0.053         0.96 (0.78--1.17)        0.689         0.89 (0.76--1.04)         0.15
   HB                   29        12,463           15,976      **0.85 (0.77--0.95)**    **0.003**     **0.86 (0.74--0.99)**     **0.04**     **0.78 (0.65--0.93)**    **0.007**     **0.88 (0.81--0.96)**    **0.004**     **0.89 (0.81--0.97)**   ****0.006****
  Ethnicity                                                                                                                                                                                                                                       
   Caucasian            12         3,413           6,887       **1.20 (1.1--1.31)**    **\<0.0001**     1.03 (0.92--1.16)        0.583       **1.15 (1.01--1.31)**     **0.03**     **1.22 (1.11--1.34)**   **\<0.0001**   **1.11 (1.04--1.17)**     **0.001**
   Asian                30        14,809           17,891      **0.77 (0.70--0.86)**   **\<0.0001**   **0.77 (0.67--0.90)**    **0.001**     **0.66 (0.55--0.80)**   **\<0.0001**   **0.85 (0.81--0.90)**   **\<0.0001**   **0.82 (0.76--0.90)**   **\<0.0001**
  Genotyping methods                                                                                                                                                                                                                              
   PCR-RFLP             11         5,450           6,525       **0.75 (0.62--0.90)**    **0.002**     **0.72 (0.60--0.87)**    **0.001**     **0.62 (0.47--0.82)**    **0.001**     **0.81 (0.70--0.94)**    **0.005**     **0.87 (0.80--0.95)**     **0.001**
   MassARRAY             3          998            1,096         0.77 (0.44--1.32)        0.334         0.93 (0.43--2.01)        0.862         0.77 (0.29--2.07)        0.608         0.75 (0.53--1.07)        0.111         0.87 (0.80--0.95)         0.609
   TaqMan               14         8,505           12,059        0.95 (0.83--1.09)        0.446         0.99 (0.83--1.21)        0.977         0.95 (0.76--1.19)        0.654         0.95 (0.84--1.07)        0.375         0.87 (0.80--0.95)         0.685
   PCR-PAGE              6         1,284           1,599                                 **0.08**     **0.65 (0.50--0.85)**    **0.002**     **0.58 (0.39--0.86)**    **0.008**       0.86 (0.66--1.12)        0.257       **0.87 (0.80--0.95)**     **0.015**
   PCR-CGE               2          241             349          0.70 (0.50--0.98)        0.037         0.61 (0.26--1.40)        0.239         0.51 (0.23--1.13)        0.096         0.78 (0.55--1.12)        0.174         0.87 (0.80--0.95)         0.017
   Pyrosequencing        4          593            1,228         1.18 (0.94--1.48)        0.146         0.96 (0.72--1.28)        0.756         1.06 (0.78--1.45)        0.693         1.23 (0.94--1.60)        0.125         0.87 (0.80--0.95)         0.364
  Quality score                                                                                                                                                                                                                                   
   [\<]{.ul}7 points    24         8,849           13,548                               **0.013**     **0.81 (0.71--0.91)**    **0.001**     **0.75 (0.63--0.89)**    **0.001**       0.91 (0.82--1.01)        0.076       **0.87 (0.80--0.95)**     **0.002**
   \>7 points           18         9,373           11,230        0.87 (0.74--1.01)        0.066         0.87 (0.70--1.08)        0.205         0.79 (0.60--1.04)        0.086         0.89 (0.78--1.01)        0.073         0.91 (0.80--1.03)         0.126
  Cancer Type                                                                                                                                                                                                                                     
   OSCC                  2          674             721        **0.60 (0.46--0.77)**   **\<0.0001**   **0.63 (0.49--0.81)**   **\<0.0001**   **0.49 (0.33--0.72)**   **\<0.0001**   **0.67 (0.51--0.88)**    **0.004**     **0.70 (0.60--0.82)**   **\<0.0001**
   CRC                   5         2,777           4,409         1.12 (0.85--1.48)        0.409         0.98 (0.76--1.26)        0.849         1.06 (0.74--1.52)        0.768         1.14 (0.87--1.49)        0.336         1.06 (0.88--1.27)         0.558
   BC                    4         1,788           1,955                                  0.884         1.16 (0.68--1.97)        0.578         1.12 (0.64--1.96)        0.692         0.95 (0.81--1.11)         0.48         1.05 (0.82--1.36)         0.686
   GC                    2          583             549          0.74 (0.24--2.31)        0.603         1.00 (0.26--3.85)        0.996         0.78 (0.12--5.12)        0.799         0.72 (0.33--1.57)         0.41         0.90 (0.34--2.24)         0.814
   HCC                   3          961            2,530         0.59 (0.30--1.15)        0.119         0.67 (0.40--1.10)        0.114         0.50 (0.21--1.16)        0.106         0.65 (0.37--1.15)        0.137         0.69 (0.44--1.09)         0.114
   PC                    4         2,207           2,358         0.79 (0.61--1.02)        0.074         0.89 (0.66--1.20)        0.447         0.72 (0.45--1.16)        0.177         0.84 (0.71--1.00)         0.05         0.88 (0.74--1.05)         0.149
   OC                    4         1,463           1,573       **0.67 (0.56--0.79)**   **\<0.0001**   **0.68 (0.52--0.89)**    **0.005**     **0.54 (0.40--0.73)**   **\<0.0001**   **0.73 (0.61--0.87)**    **0.001**     **0.75 (0.65--0.86)**   **\<0.0001**
   LC                    5         2,793           2,921         0.83 (0.67--1.03)        0.092         0.82 (0.54--1.26)        0.368         0.77 (0.48--1.26)        0.302       **0.84 (0.74--0.96)**    **0.008**       0.88 (0.70--1.09)         0.246
   NPC                   3         1,573           2,182       **0.82 (0.72--0.93)**    **0.003**     **0.74 (0.63--0.88)**   **\<0.0001**   **0.63 (0.49--0.81)**   **\<0.0001**     0.63 (0.49--0.81)        0.067       **0.83 (0.76--0.91)**   **\<0.0001**
   RCC                   2         1,356           1,895         1.01 (0.87--1.17)        0.892         1.01 (0.72--1.40)        0.973         1.06 (0.85--1.31)        0.625         1.07 (0.78--1.47)        0.688         1.02 (0.92--1.13)         0.71
   Other cancers         8         1,867           3,685         0.99 (0.78--1.27)        0.962         0.79 (0.59--1.05)         0.1          0.81 (0.55--1.21)        0.307         1.07 (0.86--1.31)        0.553         0.93 (0.77--1.13)         0.468

*OR*, odds ratio; *CI*, confidence interval.

*P* values in bold denotes significance.

^a^The *P* values of Z test for odds ratios test.

###### Summary of the corrected *P* value for multiple testing and heterogeneity test in this meta-analysis.

                        No.   Sample size (N)   DD+DI vs. II   DD vs. DI+II   DD vs. II   DI vs. II     D vs. I                                                                                                           
  -------------------- ----- ----------------- -------------- -------------- ----------- ----------- ------------- ------ ---------- ------------- ------ ---------- ------------- ------ ---------- ------------- ------ ----------
  Overall               42        18,222           24,778       **0.005**       77.1      \<0.0001    **0.0037**    80.2   \<0.0001    **0.005**    83.8   \<0.0001    **0.011**    64.1   \<0.0001    **0.005**     84    \<0.0001
  Control source                                                                                                                                                                                                          
   PB                   10         5,369           8,212          0.443         86.6      \<0.0001        0.1       81.5   \<0.0001      0.133      83.1   \<0.0001      0.689      71.3   \<0.0001      0.25       87.8   \<0.0001
   HB                   29        12,463           15,976       **0.015**       73.3      \<0.0001     **0.04**     77.5   \<0.0001   **0.0088**    79.1   \<0.0001    **0.01**     53.9   \<0.0001    **0.01**     81.2   \<0.0001
  Ethnicity                                                                                                                                                                                                               
   Caucasian            12         3,413           6,887       **\<0.001**      35.3        0.108        0.583      21.8    0.229     **0.0375**    31.9    0.136     **\<0.001**   32.8    0.128     **0.0017**     32     0.135
   Asian                30        14,809           17,891      **\<0.001**       74       \<0.0001     **0.001**    84.5   \<0.0001   **\<0.001**   86.3   \<0.0001   **\<0.001**   46.5    0.003     **\<0.001**   81.1   \<0.0001
  Genotyping methods                                                                                                                                                                                                      
   PCR-RFLP             11         5,450           6,525        **0.0025**      73.6      \<0.0001     **0.003**    71.9   \<0.0001    **0.005**    78.9   \<0.0001    **0.005**    55.7    0.012      **0.002**    80.6   \<0.0001
   MassARRAY             3          998            1,096          0.835         86.7        0.001        0.862       89    \<0.0001      1.000      89.1   \<0.0001      0.555       65     0.057        0.761       88    \<0.0001
   TaqMan               14         8,505           12,059         1.000         78.4      \<0.0001       0.977      84.2   \<0.0001      1.000      85.1   \<0.0001      1.000       69    \<0.0001      0.856      85.2   \<0.0001
   PCR-PAGE              6         1,284           1,599         **0.1**        70.1        0.005      **0.01**     39.5    0.142      **0.02**     67.1     0.01        0.257      58.6    0.034      **0.025**    72.1    0.003
   PCR-CGE               2          241             349           0.0925          0         0.722        0.239      55.7    0.133        0.16       43.6    0.183        0.218       0      0.879        0.085      13.4    0.283
   Pyrosequencing        4          593            1,228          0.365         12.4        0.331        0.756      6.9     0.358        0.866       0      0.402        0.625      27.7    0.246        0.607       0      0.472
  Quality score                                                                                                                                                                                                           
   [\<]{.ul}7 points    24         8,849           13,548       **0.016**       71.6      \<0.0001     **0.005**     61    \<0.0001    **0.003**    74.5   \<0.0001      0.076      57.5   \<0.0001   **0.0033**    76.7   \<0.0001
   \>7 points           18         9,373           11,230          0.33         78.9      \<0.0001       0.205       82    \<0.0001      0.143      85.3   \<0.0001      0.183      67.5   \<0.0001      0.158       87    \<0.0001
  Cancer Type                                                                                                                                                                                                             
   OSCC                  2          674             721        **\<0.001**        0         0.377     **\<0.001**   3.9     0.308     **\<0.001**    33     0.222      **0.004**     0       0.57     **\<0.001**   6.9      0.3
   CRC                   5         2,777           4,409          1.000          85       \<0.0001       0.849      68.3    0.013        0.96       81.4   \<0.0001      1.000      82.1   \<0.0001      0.93       84.4   \<0.0001
   BC                    4         1,788           1,955          0.884         60.8        0.054        1.000      88.4   \<0.0001      0.865      87.1   \<0.0001      1.000      11.3    0.336        0.966      85.7   \<0.0001
   GC                    2          583             549           1.000         84.4      \<0.0001       0.996      90.3   \<0.0001      1.000      91.4   \<0.0001      1.000      80.9    0.022        1.000      91.6   \<0.0001
   HCC                   3          961            2,530          0.149         92.2      \<0.0001       0.285      82.4    0.003        0.53       89.9   \<0.0001      0.137      85.5   \<0.0001      0.19       89.8   \<0.0001
   PC                    4         2,207           2,358          0.185         57.6        0.07         0.447       70     0.019        0.221      78.2    0.003        0.25       9.6     0.345        0.248      69.5     0.02
   OC                    4         1,463           1,573       **\<0.001**        0         0.462      **0.005**    51.6    0.102     **\<0.001**   39.8    0.173     **0.0012**     0      0.416     **\<0.001**   38.5    0.181
   LC                    5         2,793           2,921           0.23         69.1        0.012        0.368      86.3   \<0.0001      0.378      86.9   \<0.0001    **0.04**      12     0.337        0.41       83.2   \<0.0001
   NPC                   3         1,573           2,182        **0.0038**        0         0.504     **\<0.001**    0      0.728     **\<0.001**    0      0.561        0.067       0      0.633     **\<0.001**    0      0.426
   RCC                   2         1,356           1,895          1.000          1.9        0.313        0.973      34.2    0.218        1.000       0      0.583        1.000      53.6    0.142        1.000       0      0.945
   Other cancers         8         1,867           3,685          0.962         71.8        0.001        0.500      53.2    0.046        0.768      76.4    0.002        0.691      56.4    0.025        0.78       77.6   \<0.0001

*P* values in bold denotes significance.

^a^*P* Values were corrected to adjust for multiple testing.

^b^The value of *I*^*2*^ statistics for heterogeneity test.

^c^*P* value of the Q-test for heterogeneity test.

[^1]: These authors contributed equally to this work.
